The Leukemia & Lymphoma Society (LLS) and Acetylon Pharmaceuticals today announced a newly formed business alliance whereby Acetylon and LLS will jointly support a Phase I/II clinical trial of Acetylon’s oral selective HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma. LLS has committed to provide up to $4.85 million in milestone-tranched funding to Acetylon, and a joint clinical oversight committee will be formed. Acetylon is focused on the discovery and development of potential drug candidates based on next-generation Class II-selective HDAC inhibitors.
